BA ACMA - Ansell CEO MD
| ANSLF Stock | USD 20.80 0.20 0.95% |
Insider
BA ACMA is CEO MD of Ansell Limited
| Age | 54 |
| Phone | 61 3 9270 7229 |
| Web | https://www.ansell.com |
Ansell Management Efficiency
The company has return on total asset (ROA) of 0.0605 % which means that it generated a profit of $0.0605 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1024 %, meaning that it generated $0.1024 on every $100 dollars invested by stockholders. Ansell's management efficiency ratios could be used to measure how well Ansell manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Brian Case | Repro Med Systems | 51 | |
| Candace Matthews | AptarGroup | 61 | |
| KokKien Loh | Straumann Holding AG | 56 | |
| Jenwei Wu | AptarGroup | 64 | |
| Richard Rosenzweig | AngioDynamics | 57 | |
| Angela CPA | AtriCure | 46 | |
| Lloyd Johnson | Haemonetics | 66 | |
| Heidi Tlili | AptarGroup | 49 | |
| Tonya SPHR | AtriCure | 50 | |
| Rahma Samow | Straumann Holding AG | 44 | |
| CCEP CCEP | AtriCure | 52 | |
| Isabel MareySemper | AptarGroup | 53 | |
| Farris Maunsell | Haemonetics | 48 | |
| B Owens | AptarGroup | 66 | |
| Alastair Robertson | Straumann Holding AG | 63 | |
| Garry Nolan | Akoya Biosciences | 62 | |
| Francis Tan | Haemonetics | N/A | |
| Joseph Driscoll | Akoya Biosciences | 59 | |
| Tom Adams | Repro Med Systems | N/A | |
| Carla Burigatto | Haemonetics | N/A | |
| Josep Llorens | Haemonetics | 62 | |
Management Performance
| Return On Equity | 0.1 | |||
| Return On Asset | 0.0605 |
Ansell Limited Leadership Team
Elected by the shareholders, the Ansell's board of directors comprises two types of representatives: Ansell inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ansell. The board's role is to monitor Ansell's management team and ensure that shareholders' interests are well served. Ansell's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ansell's outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA ACMA, CEO MD | ||
| Zubair Javeed, Chief Officer | ||
| Darryl Nazareth, Senior Vice President - Research and Development, Industrial Global Business Unit and Single Use Global Business Unit | ||
| Deanna Johnston, VP Officer | ||
| John Marsden, Senior Vice President of Global Operations | ||
| BS MBA, APAC EMEA | ||
| Michael Gilleece, Senior Vice President Corporate General Counsel | ||
| Michael Evans, Director Relation | ||
| MS MA, Pres Unit | ||
| Amanda Manzoni, Chief Officer |
Ansell Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Ansell a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.1 | |||
| Return On Asset | 0.0605 | |||
| Profit Margin | 0.08 % | |||
| Operating Margin | 0.13 % | |||
| Current Valuation | 2.74 B | |||
| Shares Outstanding | 127.55 M | |||
| Shares Owned By Insiders | 1.56 % | |||
| Shares Owned By Institutions | 49.03 % | |||
| Price To Earning | 12.22 X | |||
| Price To Book | 1.59 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Ansell Pink Sheet
Ansell financial ratios help investors to determine whether Ansell Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ansell with respect to the benefits of owning Ansell security.